Related Experiment Video
Updated: May 1, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity
Kelly K Haagenson1, Jessica Wei Zhang, Zhengfan Xu
1Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Abstract:
Increased activation of ERK signaling has been reported in breast cancer models of acquired tamoxifen resistance. Here, we examined the expression of Mitogen-Activated Protein Kinase Phosphatases (MKPs) 1 and 2 following tamoxifen treatment and the effects of MKP-1/MKP-2 overexpression on tamoxifen sensitivity. Treatment of MCF7 breast cancer cells with tamoxifen increased MKP-2, but not MKP-1, protein levels. Overexpression of MKP-1 or MKP-2 inhibited estrogen-induced MCF7 cell proliferation compared to vector controls. MCF7-MKP-2 cells displayed significantly increased sensitivity to tamoxifen as compared to vector control or MCF7-MKP-1 cells. MKP-1 or MKP-2 overexpression eliminated ERK1/2 phosphorylation, suggesting that decreases in estrogen-induced proliferation of MKP-1 and MKP-2 overexpressing cells are due to ERK1/2 dephosphorylation. JNK1/2 activation was not detectable in any of these cells. These data suggest that tamoxifen-induced death of these cells is not dependent upon JNK signaling, but rather that ERK is the major MAPK driving their proliferation. MCF7-TAMR cells express higher levels of MKP-2 mRNA and protein than MCF7 cells. MKP-2 and phospho-ERK1/2 proteins are constitutively expressed in MCF7-TAMR cells, and activated JNK1/2 is not detectable. These data suggest that MKP-2 rather than MKP-1 is tamoxifen-regulated and that the elevated expression of MKP-2 in MCF7-TAMR cells potentially functions to restore tamoxifen sensitivity.
Insights
Mitogen-Activated Protein Kinase Phosphatases (MKPs) regulate breast cancer cell proliferation. MKP-2 overexpression restores tamoxifen sensitivity by dephosphorylating ERK, suggesting a therapeutic target for tamoxifen-resistant breast cancer.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Acquired tamoxifen resistance in breast cancer is linked to increased ERK signaling.
- Mitogen-Activated Protein Kinase Phosphatases (MKPs) modulate MAPK pathways.
- Understanding MKP roles is crucial for overcoming tamoxifen resistance.
Purpose of the Study:
- To investigate MKP-1 and MKP-2 expression and function in tamoxifen-treated breast cancer cells.
- To determine the impact of MKP-1/MKP-2 overexpression on tamoxifen sensitivity.
- To elucidate the role of ERK and JNK signaling in tamoxifen response.
Main Methods:
- Tamoxifen treatment of MCF7 breast cancer cells.
- Overexpression of MKP-1 and MKP-2 in MCF7 cells.
- Analysis of cell proliferation, ERK/JNK phosphorylation, and protein/mRNA levels.
Main Results:
- Tamoxifen treatment increased MKP-2 protein levels in MCF7 cells.
- MKP-1 or MKP-2 overexpression inhibited estrogen-induced proliferation and ERK1/2 phosphorylation.
- MCF7 cells overexpressing MKP-2 showed enhanced tamoxifen sensitivity.
- Elevated MKP-2 and phospho-ERK1/2 were observed in tamoxifen-resistant MCF7-TAMR cells.
Conclusions:
- MKP-2, not MKP-1, is regulated by tamoxifen and plays a key role in restoring tamoxifen sensitivity.
- ERK signaling, driven by MKP-2, is critical for breast cancer cell proliferation.
- Elevated MKP-2 in tamoxifen-resistant cells suggests a mechanism for acquired resistance.
